Clinical features and prognosis analysis of non-HIV Pneumocystis jirovecii pneumonia: a multi-center retrospective cohort study

Objective The rising global incidence of Pneumocystis jirovecii pneumonia (PJP) in HIV-negative populations, characterized by atypical presentation, rapid progression, and high mortality, poses a significant clinical challenge. This study aimed to summarize the clinical, diagnostic, and therapeutic profiles of HIV-negative PJP and identify independent prognostic factors to refine clinical management. Methods A retrospective multicenter analysis was conducted on 233 HIV-negative PJP patients from five tertiary hospitals (December 2019 – June 2025), stratified into survivors ( n = 135) and non-survivors ( n = 98). Baseline demographics, laboratory indices, imaging, diagnostic modalities, and treatments were compared. Univariate and multivariate logistic regression identified mortality risk factors. Results The cohort (167 males, 66 females; mean age 53.00 ± 18.25 years) had a median symptom-to-admission time of 5 days and median hospital stay of 18 days. Underlying diseases were present in 84.55%. Atypical symptoms were common; 66.09% had an oxygenation index <300 mmHg (median 217.03; IQR 109.72–325.70), and 28.33% were 1,3- β -D-glucan positive. Significant intergroup differences ( P < 0.05) were observed for several laboratory and physiological parameters, including platelet count (PLT), procalcitonin (PCT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), oxygenation index (OI), 1,3- β -D-glucan (BDG), and tachypnea (≥30/min). Imaging revealed ground-glass opacities, patchy shadows, and septal thickening; pleural effusion, consolidation, and nodules differed significantly between groups ( P < 0.05). Among 197 mNGS-tested patients, polymicrobial co-detection was common, with viral, bacterial, and fungal positivity rates of 69.04%, 38.07%, and 26.40%, respectively; EBV, H. parainfluenzae , and P. aeruginosa were more frequently co-detected in non-survivors ( P < 0.05). Treatments, including antivirals, immunoglobulins, and mechanical ventilation, differed significantly ( P < 0.05). Multivariate analysis identified smoking history (OR = 1.818, 95% CI: 1.043–3.170, P = 0.035), shock (OR = 2.787, 95% CI: 1.453–5.348, P = 0.002), underlying pulmonary disease (OR = 3.488, 95% CI: 1.864–6.524, P < 0.001), positive BALF EBV nucleic acid (OR = 6.635, 95% CI: 1.281–34.362, P = 0.024), AST (OR = 1.033, 95% CI: 1.025–1.042, P < 0.001), and tachypnea ≥30/min (OR = 2.520, 95% CI: 1.286–4.938, P = 0.007) as independent mortality risk factors. The multivariable model achieved an AUC of 0.857 from ROC analysis. Conclusion HIV-negative PJP presents with nonspecific features and frequent polymicrobial co-detection of pathogens, contributing to high 28-day all-cause mortality. BALF mNGS can simultaneously detect Pneumocystis jirovecii and polymicrobial co-pathogens in immunocompromised patients, yet this retrospective cohort was not designed as a diagnostic accuracy trial; mNGS can only act as an auxiliary pathogen detection tool rather than a universal early screening test for suspected PJP. Close monitoring of these identified exploratory risk factors and timely targeted interventions are crucial for improving prognosis. Further external-cohort validations are warranted before applying these markers for clinical risk stratification.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-17
DOI
https://doi.org/10.3389/fmed.2026.1986196
Primary Topic
Pneumocystis jirovecii pneumonia detection and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical features and prognosis analysis of non-HIV Pneumocystis jirovecii pneumonia: a multi-center retrospective cohort study

Qicai Guo, Zuotao Li, Yanquan Liu, Huang He et al.
5 links
Frontiers in Medicine
Pneumocystis jirovecii pneumonia detection and treatment
article

Clinical features and prognosis analysis of non-HIV Pneumocystis jirovecii pneumonia: a multi-center retrospective cohort study

Qicai Guo, Zuotao Li, Yanquan Liu, Huang He, Xiaojun Chen, Zhenyuan Xu, Yue Yin, Hongying Hu, Chenfeng Wei, Jianzhen Shen
article en

Abstract

Objective The rising global incidence of Pneumocystis jirovecii pneumonia (PJP) in HIV-negative populations, characterized by atypical presentation, rapid progression, and high mortality, poses a significant clinical challenge. This study aimed to summarize the clinical, diagnostic, and therapeutic profiles of HIV-negative PJP and identify independent prognostic factors to refine clinical management. Methods A retrospective multicenter analysis was conducted on 233 HIV-negative PJP patients from five tertiary hospitals (December 2019 – June 2025), stratified into survivors ( n = 135) and non-survivors ( n = 98). Baseline demographics, laboratory indices, imaging, diagnostic modalities, and treatments were compared. Univariate and multivariate logistic regression identified mortality risk factors. Results The cohort (167 males, 66 females; mean age 53.00 ± 18.25 years) had a median symptom-to-admission time of 5 days and median hospital stay of 18 days. Underlying diseases were present in 84.55%. Atypical symptoms were common; 66.09% had an oxygenation index <300 mmHg (median 217.03; IQR 109.72–325.70), and 28.33% were 1,3- β -D-glucan positive. Significant intergroup differences ( P < 0.05) were observed for several laboratory and physiological parameters, including platelet count (PLT), procalcitonin (PCT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), oxygenation index (OI), 1,3- β -D-glucan (BDG), and tachypnea (≥30/min). Imaging revealed ground-glass opacities, patchy shadows, and septal thickening; pleural effusion, consolidation, and nodules differed significantly between groups ( P < 0.05). Among 197 mNGS-tested patients, polymicrobial co-detection was common, with viral, bacterial, and fungal positivity rates of 69.04%, 38.07%, and 26.40%, respectively; EBV, H. parainfluenzae , and P. aeruginosa were more frequently co-detected in non-survivors ( P < 0.05). Treatments, including antivirals, immunoglobulins, and mechanical ventilation, differed significantly ( P < 0.05). Multivariate analysis identified smoking history (OR = 1.818, 95% CI: 1.043–3.170, P = 0.035), shock (OR = 2.787, 95% CI: 1.453–5.348, P = 0.002), underlying pulmonary disease (OR = 3.488, 95% CI: 1.864–6.524, P < 0.001), positive BALF EBV nucleic acid (OR = 6.635, 95% CI: 1.281–34.362, P = 0.024), AST (OR = 1.033, 95% CI: 1.025–1.042, P < 0.001), and tachypnea ≥30/min (OR = 2.520, 95% CI: 1.286–4.938, P = 0.007) as independent mortality risk factors. The multivariable model achieved an AUC of 0.857 from ROC analysis. Conclusion HIV-negative PJP presents with nonspecific features and frequent polymicrobial co-detection of pathogens, contributing to high 28-day all-cause mortality. BALF mNGS can simultaneously detect Pneumocystis jirovecii and polymicrobial co-pathogens in immunocompromised patients, yet this retrospective cohort was not designed as a diagnostic accuracy trial; mNGS can only act as an auxiliary pathogen detection tool rather than a universal early screening test for suspected PJP. Close monitoring of these identified exploratory risk factors and timely targeted interventions are crucial for improving prognosis. Further external-cohort validations are warranted before applying these markers for clinical risk stratification.

Frontiers in MedicineVol. 13
Nanchang University (CN), Guangdong Medical College (CN), Ganzhou People's Hospital (CN), Gannan Medical University (CN), First Affiliated Hospital of Gannan Medical University (CN), Union Hospital (CN), Putian University (CN)
Putian University, Fujian Medical University, Health Commission of Jiangxi Province, Gannan Medical University
Good health and well-being
Pneumocystis jirovecii pneumonia detection and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon